Pharmacometrics Meets Health Economics:
Quantitative Approaches in the Translation from Efficacy to Real World Effectiveness and to Cost-Effective Patient Care

Organizing Committee: Jing Liu, Richard Willke, Scott Marshall
Co-Sponsors: ASCPT QP and DRO Networks; ISPOR
Breaking down the barriers to cost-effective patient care

Pathway | Target | Drug | Benefit/Risk

'Right Pathway' | 'Right Target' | 'Right Molecule' | 'Right Dose'

'Right Patients'

Effectiveness & Reimbursement

Adapted from Milligan, et al. CPT 2013
<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter</th>
</tr>
</thead>
</table>
| 1:00 pm | Opening Remarks                                                      | Jing Liu, PhD  
                    Senior Director, Clinical Pharmacology, Pfizer |
| 1:05 pm | Background/Introduction: Role of Pharmacometrics and Health Economics for Cost-Effective Patient Care | Richard Willke, PhD  
                    Chief Scientific Officer, ISPOR |
| 1:20 pm | Understanding the Comparative Efficacy and Effectiveness via Meta-Analysis: Health Economics Approach | Jeroen P. Jansen, PhD, MSc  
                    Chief Scientist, Precision Health Economics |
| 1:50 pm | Understanding the Comparative Efficacy and Effectiveness via Model-Based Meta-Analysis: Pharmacometrics approach | Jaap Mandema, PhD  
                    Chief Innovation Officer, Certara |
| 2:20 pm | Linking Pharmacometrics and Health Economics: Quantitative Approaches to Cost-Effectiveness Evaluations of Health Care Decisions | Dyfrig Hughes, PhD  
                    Professor, Centre for Health Economics and Medicines Evaluation, University of Bangor, UK |
| 2:50 pm | Break                                                              |                                                                           |
| 3:10 pm | Leveraging Novel Simulation Techniques to Incorporate Pharmacometrics in Pharmacoeconomic Models | Jaime Caro, MDCM, FRCPC, FACP  
                    Chief Scientist, Evidera |
| 3:40 pm | Industry Perspectives: Examples on How to Assess Values in Drug Development | Neeta Tandon, MA  
                    Senior Director, Health Economics & Outcomes Research, Janssen Pharmaceuticals, Inc. |
| 4:10 pm | Panel Discussion: Can Linked Pharmacometric-Health Economic Evidence Improve Early Evaluation of New Medicines? | Leader: Scott Marshall, PhD  
                    Executive Director, Pharmacometrics, Pfizer, UK  
                    Panelists: all speakers |
| 4:50 pm | Closing Remarks                                                | Jing Liu, PhD |